Clarius Group LLC Has $481,000 Position in Pfizer Inc. (NYSE:PFE)

Clarius Group LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 38.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,001 shares of the biopharmaceutical company's stock after selling 11,746 shares during the period. Clarius Group LLC's holdings in Pfizer were worth $481,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC raised its holdings in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the 4th quarter worth approximately $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.5%

NYSE PFE traded down $0.13 on Thursday, hitting $23.88. 37,055,113 shares of the company were exchanged, compared to its average volume of 41,246,625. The company has a market cap of $135.74 billion, a PE ratio of 17.30, a PEG ratio of 0.87 and a beta of 0.57. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a fifty day moving average of $23.17 and a 200-day moving average of $24.92. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter last year, the firm posted $0.82 EPS. Pfizer's revenue was down 7.8% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.20%. The ex-dividend date was Friday, May 9th. Pfizer's payout ratio is currently 124.64%.

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.